Another Nrf2 activator oltipraza is reported to prevent, intervene and mitigate colon and liver cancer, hepatic fibrosis and nonalcoholic fatty liver disease (NAFLD) [138]. This evidence concerns the gene NFE2L2 and Hepatic fibrosis.